Cue Biopharma Reports Strong Q4 Revenue & Reduced Annual Loss, Bolstered by $15M Collaboration and $10.2M Capital Raise

summarizeSummary

Cue Biopharma reported significantly improved Q4 2025 financial results, including positive net income, driven by a new $15 million strategic collaboration and a $10.2 million capital raise, substantially boosting its cash position.

check_boxKey Events

• Strong Q4 2025 Financial Performance

  The company reported collaboration revenue of $21.9 million for Q4 2025, a significant increase from $1.6 million in Q4 2024, resulting in a net income of $1.585 million for the quarter, compared to a net loss of $9.496 million in the prior year period.

• Reduced Full Year 2025 Net Loss

  For the full year 2025, Cue Biopharma reduced its net loss to $26.6 million from $40.7 million in 2024, with total collaboration revenue reaching $27.5 million.

• Strategic Collaboration with ImmunoScape

  Announced a collaboration and license agreement with ImmunoScape, entitling Cue Biopharma to $15 million in upfront payments ($9.5 million received in Q4 2025) and a 40% equity stake in ImmunoScape, plus high-single digit royalties.

• Successful Capital Raise

  The company raised net proceeds of $10.2 million through an underwritten public offering, significantly bolstering its cash reserves.

auto_awesomeAnalysis

Cue Biopharma's Q4 and full-year 2025 financial results show a significant turnaround, driven by a substantial strategic collaboration and a successful capital raise. The company reported positive net income for Q4 2025 and a reduced net loss for the full year, largely due to $21.9 million in collaboration revenue for the quarter. A key driver is the strategic collaboration and license agreement with ImmunoScape, which includes $15 million in upfront payments (with $9.5 million already received) and a 40% equity stake in ImmunoScape, along with future royalties. Additionally, the company raised $10.2 million through an underwritten public offering. These significant cash inflows, totaling over $25 million, are transformational for a company with a market capitalization of approximately $28.5 million, directly addressing liquidity concerns. While the company still acknowledges a 'going concern' determination in its forward-looking statements, these financial and strategic developments provide a crucial lifeline and extend its operational runway. This positive news comes shortly after a PRE 14A filing on March 6, 2026, seeking stockholder approval for a reverse stock split to maintain Nasdaq listing, suggesting these financial improvements could be aimed at bolstering investor sentiment ahead of that critical vote.